InvestorsHub Logo
Followers 11
Posts 546
Boards Moderated 0
Alias Born 08/18/2017

Re: None

Wednesday, 12/30/2020 1:23:53 PM

Wednesday, December 30, 2020 1:23:53 PM

Post# of 704472
Merck's Disappointing 2020

"The spinoff will heighten Merck’s reliance on Keytruda, which grew sales 21% in the September quarter and accounted for 30% of the company’s revenue."

"Merck has said it would use its ample cash to build its oncology franchise by joining with firms like Seagen (SGEN) on drug-antibody combinations, and Moderna for messenger-RNA cancer therapies. It will also bring in oncology products through “bolt-on” acquisitions like the purchase of ArQule at the start of 2020.

Vaccines will remain a big business for Merck..."

https://www.barrons.com/articles/merck-had-a-disappointing-2020-why-its-strategy-could-pay-off-in-2021-51609347863
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News